Skip to main content
SpringerLink
Log in

The Expanding Role of Sp1 in Pancreatic Cancer: Tumorigenic and Clinical Perspectives

  • Chapter
  • First Online:
Role of Transcription Factors in Gastrointestinal Malignancies

  • 472 Accesses

Abstract

It is increasingly being recognized that in gastrointestinal malignancies, including pancreatic cancer, transcription factors get activated and alter the gene expression in the tumor cells to metastasize and develop. Pancreatic cancer is associated with a relatively very poor prognosis and survival outcomes. Currently, there are significant barriers to effective therapeutic interventions for this disease; hence timely diagnosis and clinical decision-making leading to appropriate treatment strategies for patients with metastatic pancreatic cancer are essential. This chapter summarizes some of the selected peer-reviewed translational and clinical research findings in the area of a transcription factor [specificity protein 1 (Sp1)] as it relates to the tumorigenesis and mechanistic role(s) for the potential of improving therapeutic targets/responses in pancreatic cancer. Particular emphasis has been given on the mechanistic roles of Sp1 in the cell cycle, metastasis (cellular adhesion, invasion, migration, angiogenesis), and apoptosis. Based on the available information and several ongoing clinical studies, it is implicated that Sp1 can well serve as an important prognostic marker for pancreatic tumor. Several drugs targeting Sp1 for pancreatic tumor therapy have also been studied and discussed in this chapter. These drugs work by downregulating the expression and activity of Sp1 in tumor cells in pancreatic cancer. Taken together, these molecular and cellular mechanisms/targets can have a very significant impact on the prognosis and overall quality-of-life and clinical outcomes for patients with pancreatic tumor.

The original version of this chapter was revised. The book was inadvertently published without Abstracts and Keywords, which are now included in all the chapters. An erratum to this chapter can be found at https://doi.org/10.1007/978-981-10-6728-0_39

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98:855–868

    Article  CAS  PubMed  Google Scholar 

  2. Abdelrahim M, Smith R, Burghardt R, Safe S (2004) Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 64:6740–6749

    Article  CAS  PubMed  Google Scholar 

  3. Aghdassi A, Phillips P, Dudeja V, Dhaulakhandi D, Sharif R, Dawra R et al (2007) Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res 67:616–625

    Article  CAS  PubMed  Google Scholar 

  4. Banerjee S, Sangwan V, McGinn O, Chugh R, Dudeja V, Vickers SM et al (2013) Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1. J Biol Chem 288:33927–33938

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR et al (2011) Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 122:163–170

    Article  CAS  PubMed  Google Scholar 

  6. Bünger S, Laubert T, Roblick UJ, Habermann JK (2011) Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 137:375–389

    Article  CAS  PubMed  Google Scholar 

  7. Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ et al (2011) Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Investig New Drugs 29:41–51

    Article  CAS  Google Scholar 

  8. Hang J, Hu H, Huang J, Han T, Zhuo M, Zhou Y et al (2016) Sp1 and COX-2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma. Oncotarget 7:28207–28217

    PubMed  PubMed Central  Google Scholar 

  9. Hedrick E, Cheng Y, Jin U-H, Kim K, Safe S (2016) Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cells. Oncotarget 7:22245–22256

    Article  PubMed  PubMed Central  Google Scholar 

  10. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S (2006) Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun 345:292–301

    Article  CAS  PubMed  Google Scholar 

  11. Hu H, Han T, Zhuo M, Wu L-L, Yuan C, Wu L et al (2017) Elevated COX-2 expression promotes angiogenesis through EGFR/p38-MAPK/Sp1-dependent signalling in pancreatic cancer. Sci Rep 7(1):470. https://doi.org/10.1038/s41598-017-00288-4

    Article  PubMed  PubMed Central  Google Scholar 

  12. Hu J, Hu H, J-j H, Yang H-y, Wang Z-y, Wang L et al (2016) Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients. Oncotarget 7:78557–78565

    PubMed  PubMed Central  Google Scholar 

  13. Huang C, Xie K (2012) Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev 23:25–35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D (2008) Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Preven Biomark 17:1648–1652

    Article  CAS  Google Scholar 

  15. Jungert K, Buck A, von Wichert G, Adler G, König A, Buchholz M et al (2007) Sp1 is required for transforming growth factor-β–induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 67:1563–1570

    Article  CAS  PubMed  Google Scholar 

  16. Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A et al (2017) Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 35:2324–2328

    Article  PubMed  Google Scholar 

  17. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A et al (2009) Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 30:1193–1201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Pietrasz D, Pécuchet N, Garlan F, Didelot A, Dubreuil O, Doat S et al (2017) Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res 23:116–123

    Article  CAS  PubMed  Google Scholar 

  19. Pishvaian MJ, Brody JR (2017) Therapeutic implications of molecular subtyping for pancreatic cancer. Oncology (Williston Park) 31:159–168

    Google Scholar 

  20. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–2921

    Article  CAS  Google Scholar 

  21. Safe S, Abdelrahim M (2005) Sp transcription factor family and its role in cancer. Eur J Cancer 41:2438–2448

    Article  CAS  PubMed  Google Scholar 

  22. Sankpal UT, Ingersoll SB, Ahmad S, Holloway RW, Bhat VB, Simecka JW et al (2016) Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin a novel combination for inhibiting epithelial ovarian cancer cell proliferation. Tumor Biol 37:14259–14269

    Article  CAS  Google Scholar 

  23. Sankpal UT, Goodison S, Jones-Pauley M, Hurtado M, Zhang F, Basha R (2017) Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells. Oncotarget 8:14593–14603

    Article  PubMed  PubMed Central  Google Scholar 

  24. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian C-N, Tang H et al (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61:4143–4154

    CAS  PubMed  Google Scholar 

  25. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30

    Article  Google Scholar 

  26. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K (2004) Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64:2030–2038

    Article  CAS  PubMed  Google Scholar 

  27. Weinberg BA, Philip PA, Salem ME (2017) Evolving standards of care for resected pancreatic cancer. Clin Adv Hematol Oncol 15:141–150

    PubMed  Google Scholar 

  28. Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q et al (2007) Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 110:2682–2690

    Article  CAS  PubMed  Google Scholar 

  29. Zhang X, Li Y, Dai C, Yang J, Mundel P, Liu Y (2003) Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney. Am J Physiol 284:F82–F94

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Khyber Teaching Hospital, Peshawar, Pakistan

    Abdul Rauf

  2. Department of Internal Medicine, Florida Hospital, Orlando, FL, USA

    Saeed Ali &  Asad-ur-Rahman

  3. Lady Reading Hospital, Peshawar, Pakistan

    Muhammad Talha Khan

  4. UCF and FSU Colleges of Medicine, FH Gynecologic Oncology, Florida Hospital, Orlando, FL, USA

    Sarfraz Ahmad

Authors
  1. Abdul Rauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saeed Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Muhammad Talha Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Asad-ur-Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sarfraz Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarfraz Ahmad .

Editor information

Editors and Affiliations

  1. Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA

    Ganji Purnachandra Nagaraju

  2. Department of Biotechnology, Krishna University, Machilipatnam, Andhra Pradesh, India

    Pallaval Veera Bramhachari

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rauf, A., Ali, S., Khan, M.T., Asad-ur-Rahman, Ahmad, S. (2017). The Expanding Role of Sp1 in Pancreatic Cancer: Tumorigenic and Clinical Perspectives. In: Nagaraju, G., Bramhachari, P. (eds) Role of Transcription Factors in Gastrointestinal Malignancies. Springer, Singapore. https://doi.org/10.1007/978-981-10-6728-0_29

Download citation

Publish with us

Policies and ethics

Search

Navigation